Peter G. Miller,Murugappan Sathappa,Jamie A. Moroco,Wei Jiang,Yue Qian,Sumaiya Iqbal,Qi Guo,Andrew O. Giacomelli,Subrata Shaw,Camille Vernier,Besnik Bajrami,Xiaoping Yang,Cerise Raffier,Adam S. Sperling,Christopher J. Gibson,Josephine Kahn,Cyrus Jin,Matthew Ranaghan,Alisha Caliman,Merissa Brousseau,Eric S. Fischer,Robert Lintner,Federica Piccioni,Arthur J. Campbell,David E. Root,Colin W. Garvie,Benjamin L. Ebert

Abstract:Abstract PPM1D encodes a serine/threonine phosphatase that regulates numerous pathways including the DNA damage response and p53. Activating mutations and amplification of PPM1D are found across numerous cancer types. GSK2830371 is a potent and selective allosteric inhibitor of PPM1D, but its mechanism of binding and inhibition of catalytic activity are unknown. Here we use computational, biochemical and functional genetic studies to elucidate the molecular basis of GSK2830371 activity. These data confirm that GSK2830371 binds an allosteric site of PPM1D with high affinity. By further incorporating data from hydrogen deuterium exchange mass spectrometry and sedimentation velocity analytical ultracentrifugation, we demonstrate that PPM1D exists in an equilibrium between two conformations that are defined by the movement of the flap domain, which is required for substrate recognition. A hinge region was identified that is critical for switching between the two conformations and was directly implicated in the high-affinity binding of GSK2830371 to PPM1D. We propose that the two conformations represent active and inactive forms of the protein reflected by the position of the flap, and that binding of GSK2830371 shifts the equilibrium to the inactive form. Finally, we found that C-terminal truncating mutations proximal to residue 400 result in destabilization of the protein via loss of a stabilizing N- and C-terminal interaction, consistent with the observation from human genetic data that nearly all PPM1D mutations in cancer are truncating and occur distal to residue 400. Taken together, our findings elucidate the mechanism by which binding of a small molecule to an allosteric site of PPM1D inhibits its activity and provides insights into the biology of PPM1D.

PPM1D activity promotes cellular transformation by preventing senescence and cell death

Reversal of the ATM/ATR-mediated DNA Damage Response by the Oncogenic Phosphatase PPM1D.

PPM1D regulates p21 expression via dephoshporylation at serine 123.

Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice.

Inhibition of Nonsense-Mediated Decay Rescues Functional P53β/γ Isoforms in MDM2-amplified Cancers

PPM1D Dephosphorylates Chk1 and P53 and Abrogates Cell Cycle Checkpoints.

Inhibition of Nonsense-Mediated Decay Rescues P53β/γ Isoform Expression and Activates the P53 Pathway in MDM2-overexpressing and Select P53-Mutant Cancers

Inhibition of nonsense-mediated decay rescues p53/ isoform expression and activates the p53 pathway in and select-mutant cancers

Targeting Mouse Double Minute 2: Current Concepts in DNA Damage Repair and Therapeutic Approaches in Cancer.

The role of PPM1D in cancer and advances in studies of its inhibitors

The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphoma

Targeting PPM1D by lentivirus-mediated RNA interference inhibits the tumorigenicity of bladder cancer cells.

Overexpression of PPM1B inhibited chemoresistance to temozolomide and proliferation in glioma cells

Regulation of the PML tumor suppressor in drug-induced senescence of human normal and cancer cells by JAK/STAT-mediated signaling

Depletion of Paraspeckle Protein 1 Enhances Methyl Methanesulfonate-Induced Apoptosis Through Mitotic Catastrophe

The P53-Induced Oncogenic Phosphatase PPM1D Interacts with Uracil DNA Glycosylase and Suppresses Base Excision Repair.

Allosteric inhibition of PPM1D serine/threonine phosphatase via an altered conformational state

Crystal structure and mechanistic studies of the PPM1D serine/threonine phosphatase catalytic domain

A CANCER PERSISTENT DNA REPAIR CIRCUIT DRIVEN BY MDM2, MDM4 (MDMX), AND MUTANT P53 FOR RECRUITMENT OF MDC1 AND 53BP1 TO CHROMATIN

Protein Phosphatase 1 Inhibits P53 Signaling by Dephosphorylating and Stabilizing Mdmx

Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib.